Psychedelic Compound DOI Shows Promise in Reducing Anxiety
- RHIZE
- Nov 30, 2024
- 3 min read
A New Discovery: Psychedelic Compound DOI Shows Promise in Reducing Anxiety
In the ever-evolving world of psychedelics and their therapeutic potential, researchers have uncovered exciting new findings. A compound known as DOI (2,5-dimethoxy-4-iodoamphetamine), which shares similarities with LSD, has demonstrated the ability to reduce anxiety in mice by altering brain activity in specific ways. These findings, published in the journal Neuron, could pave the way for groundbreaking treatments for anxiety in humans—potentially without causing hallucinations.
How DOI Works: Targeting Anxiety at the Source
The study revealed that DOI activates specialized brain cells called fast-spiking interneurons in the ventral hippocampus, a region of the brain linked to emotions and memory. This activation leads to the silencing of other nearby neurons that are often overactive in anxious states. The result? A measurable reduction in anxiety behavior in rodents.
This targeted action suggests that some of the therapeutic effects of psychedelics may rely on brain pathways distinct from those that cause hallucinations. This discovery raises an intriguing possibility: psychedelic-inspired drugs could be developed to alleviate anxiety without the vivid sensory effects typically associated with psychedelics.
Testing DOI’s Effects in Rodents
Researchers used a classic anxiety test involving a maze. Typically, anxious rodents spend more time in the enclosed areas of the maze, avoiding the open spaces. After being administered DOI, the rodents displayed less anxiety-related behavior, venturing more confidently into the open sections.
To further investigate, the researchers injected DOI directly into different regions of the brain. They found that activating specific interneurons in the hippocampus alone was enough to reduce anxiety behavior, even without the full psychedelic compound.
Why This Matters for Psychedelic Therapy
Psychedelics like LSD and psilocybin have gained attention for their potential to treat mental health conditions such as anxiety, depression, and PTSD. These substances are structurally similar to serotonin, a key neurotransmitter that regulates mood and perception. By disrupting typical brain communication patterns, psychedelics increase connectivity between regions that don’t usually interact, leading to therapeutic effects and, in some cases, hallucinations.
However, hallucinations remain a barrier for some people considering psychedelic therapy. The findings from the DOI study highlight the potential to create treatments that retain the therapeutic benefits of psychedelics without the accompanying sensory effects.
A Step Toward Anxiety-Specific Treatments
One of the most promising aspects of this study is its focus on the ventral hippocampus. Unlike other regions of the brain affected by psychedelics, this area seems to influence anxiety without contributing to hallucinations. By honing in on this pathway, researchers could design drugs that offer anxiety relief while avoiding the challenges associated with psychedelic experiences.
As co-author Vidita Vaidya explains, “Simply activating these neurons within the ventral hippocampus, even in the absence of psychedelics, is sufficient to reduce anxiety behavior. That opens up the possibility to design psychedelic-inspired drugs that target anxiety without evoking potent hallucinations.”
The Future of Psychedelic Research
DOI is just one example of how psychedelics are unlocking new possibilities for mental health treatment. While much of the current focus has been on psilocybin and LSD, compounds like DOI are expanding our understanding of how these substances work at a cellular level.
By identifying the brain circuits and cell types involved in anxiety reduction, researchers are laying the groundwork for next-generation therapies that are both safe and effective. With continued research, we may see the development of non-hallucinogenic drugs inspired by psychedelics, offering new hope for individuals struggling with anxiety.
At RHIZE Mushroom, we celebrate these advancements and remain committed to supporting safe, informed exploration of natural and psychedelic-based wellness. As the field of psychedelic therapy continues to grow, the possibilities for mental health innovation are endless.
Comments